CEO
Anocca
Anocca develops precision T-cell receptor engineered therapies (TCR-T) to target and treat untreatable cancers by replicating T-cell biology in the lab and utilizing custom software for precise disease target identification. Their approach addresses the need for effective cancer therapeutics by harnessing the natural ability of T-cells to recognize and attack cancer cells.
- Biotechnology
- Software Only
Updated 23 months ago
Funding
Raised to date
$36.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many cancers remain untreatable due to a lack of effective therapies that can specifically target and eliminate cancer cells without harming healthy tissues. Traditional cancer treatments often have limited efficacy and significant side effects, highlighting the need for more precise and targeted approaches.
Solution
Anocca is developing precision T-cell receptor (TCR) engineered therapies (TCR-T) to address untreatable cancers. The company replicates T-cell biology in the lab and utilizes custom software for precise disease target identification. This approach harnesses the natural ability of T-cells to recognize disease targets inside cancer cells, opening a rich source of therapeutic targets for precision cancer therapeutics. Anocca combines novel biotechnologies with integrated software to identify disease targets and build T-cell immunotherapies.
Target Audience
The primary target audience includes patients with untreatable cancers and healthcare providers seeking more effective and targeted cancer therapies.
Features
- Engineered T-cell receptor (TCR) therapies for targeting cancer cells.
- Replication of T-cell biology in the lab to enhance therapeutic efficacy.
- Custom software for precise disease target identification.
- Modular biotechnologies for systematic TCR-T discovery.
- Integrated software ecosystem for comprehensive analysis.